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Ellagic acid: A potent glyoxalase-I inhibitor with  
a unique scaffold
The glyoxalase system, particularly glyoxalase-I (GLO-I), 
has been approved as a potential target for cancer treat-
ment. In this study, a set of structurally diverse polyphe-
nolic natural compounds were investigated as potential 
GLO-I inhibitors. Ellagic acid was found, computationally 
and experimentally, to be the most potent GLO-I inhibitor 
among the tested compounds which showed an IC50 of 0.71 
mmol L–1. Its binding to the GLO-I active site seemed to be 
mainly driven by ionic interaction via its ionized hydroxyl 
groups with the central Zn ion and Lys156, along with 
other numerous hydrogen bonding and hydrophobic inter-
actions. Due to its unique and rigid skeleton, it can be 
 utilized to search for other novel and potent GLO-I inhi-
bitors via computational approaches such as pharmaco-
phore modeling and similarity search methods. Moreover, 
an inspection of the docked poses of the tested compounds 
showed that chlorogenic acid and dihydrocaffeic acid 
could be considered as lead compounds worthy of further 
optimization.
Keywords: ellagic acid, glyoxalase-I, zinc-binding, antican-
cer, molecular docking, MM-GBMV
The glyoxalase system is a ubiquitous detoxifying pathway in which reactive meta-
bolic aldehydes are detoxified. It consists of two consecutive thiol-dependent zinc coor-
dinating metalloenzymes, namely, glyoxalase I (GLO-I) and glyoxalase II (GLO-II) (1). 
The detoxification is accomplished by converting the toxic glycolysis by-product methyl-
glyoxal to S-D-lactoyl-glutathione (SLG). The process proceeds by GLO-I catalyzed isome-
rization of thiohemiacetal, which is formed spontaneously from methylglyoxal and GSH, 
into S-D-lactoyl-glutathione. Then, GLO-II catalyzes the hydrolysis of SLG releasing the 
non-toxic D-lactic acid and regenerating GSH cofactor (1, 2). Since the accumulation of 
methylglyoxal and similar oxoaldehydes is deleterious to cell viability, targeting the 
 glyoxalase system with potent inhibitors presents a potential goal especially for the 
 treatment of oncotic disorders where the cellular production of these toxic metabolites is 
abnor mally high (3–7).
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Fig. 1. a) The human GLO-I crystal structure (PDB code 3W0T). The protein is shown in cartoon rep-
resentation where chain A and chain B are colored in deep salmon and light blue, resp. The HPU is 
shown in balls and sticks, and Zn2+ ions as purple spheres; b) Surface depiction of the GLO-I enzyme 
showing the location of the binding site at the dimer interface; c) A close-up view of the active site 
showing the coordination geometry of the Zn2+ ion and the amino acid residues (ball and stick) and 
HPU (sticks) involved in this coordination; d) Surface depiction of the GLO-I active site (PDB code 
1QIN) illustrating the three major binding regions. The hydrophobic pocket is colored brown, the 
zinc atom is shown as a purple sphere, and the positively charged mouth is colored blue with relevant 
amino acid residues are shown as sticks. The co-crystallized ligand that coordinates the Zn atom is 
in balls and sticks with green carbon atoms.
Structurally, the GLO-I enzyme is a homodimeric mononuclear zinc-coordinating 
 metalloenzyme with each monomer comprising 183 residues, and the active site is located 
at the interface of the two chains. The central zinc ion within the active site coordinates 
4 amino acid residues from both chains (8) (Fig. 1a,b). When co-crystallized with HPU 
 (N-hydroxypyridone derivative, PDB entry code 3W0T), two additional dative bonds  between 
the zinc ion and the ligand align the geometry of coordination with a perfect octahedral 
(Fig. 1c). Moreover, the active site of the GLO-I enzyme can be divided into a deep hydro-
phobic region, a central zinc atom, and a positively charged mouth (Fig. 1d).
Our research group has been targeting the GLO-I enzyme for almost a decade where 
a large number of diverse compounds have been designed, synthesized and screened (6, 
9–15). In this study, we build on our previous work of searching for potent GLO-I inhibi-
tors of which natural flavonoids had demonstrated superior affinity to the GLO-I active 
site, thus serving as a potent inhibitor for the bioconversion of methylglyoxal and as po-
tential anticancer agents (9, 11, 12). Previously, we investigated the structure-activity rela-
tionship of flavonoids as potential GLO-I inhibitors and found that the multiple electro-
a)                                                                  b)
 
 
c)                                                                d)
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negative polar oxygen centers are expected to coordinate well with the positively charged 
zinc ion. In addition, their nearly rigid skeleton and their geometry that fit the enzyme 
hydrophobic pocket had explained their tight binding to the GLO-I active site (11). The 
accumulated evidence of the inhibitory potential of polyphenolic natural compounds, 
such as flavonoids, against the GLO-I enzyme, has encouraged us to proceed further in 
this direction. Therefore, a set of structurally diverse polyphenolic natural compounds 
that have never been tested against GLO-I enzyme were selected to further validate and 
investigate, computationally and experimentally, the impact of ionizability and struc-
tural rigidity of polyphenolic compounds on their GLO-I inhibitory potential. Moreover, 
we aimed to search for new scaffolds of natural compounds that can be of therapeutic 
potential as potent GLO-I inhibitors.
EXPERIMENTAL
Materials and software
Seven of the selected compounds were purchased from Combi-Blocks, Inc. (USA), 
Sigma-Aldrich (USA), Acros Organics (Belgium), Santa Cruz Biotechnology, Inc. (USA), 
and Toronto Research Chemicals Inc. (Canada). Isosylibin A, silychristin, and isosily-
christin were a kind gift from Dr. Nicholas H. Oberlies, the University of North Carolina 
at Greensboro (USA).
In vitro assay of the selected compounds was performed against the human recom-
binant GLO-I (rhGLO-I), E. coli-derived Ala2-Met184, with an N-terminal Met and 6-His 
tag (R&D Systems® Corporation, USA) using a double-beam UV-Vis spectrophotometer 
(Biotech Engineering Management Co. Ltd. Cyprus).
Preparation of the GLO-I crystal structure was performed using Discovery Studio 
(DS) 2017 (Dassault Systèmes BIOVIA, Discovery Studio Modeling Environment, Release 
2017, Dassault Systèmes, 2016, USA). Solvation of the GLO-I enzyme was performed using 
the Solvate protocol within DS. Minimization of the solvated GLO-I model was per-
formed using the smart minimizer algorithm within the Minimization protocol that uses 
the CHARMm force field (16) implemented in DS MD protocols. QM-based atomic charge 
calculations were performed using the Calculate Energy (DFT) protocol within DS. Mo-
lecular docking was performed using CDOCKER docking protocols within DS. MM-
GBMV binding energy calculations were performed using calculate binding energy pro-
tocol in DS (17). Presentation quality images were generated using PyMOL (The PyMOL 
Molecular Graphics System, Version 0.99 Schrödinger, LLC) and DS. GraphPad Prism 
(GraphPad Software: La Jolla (CA), USA) was used for calculation of the % of enzyme 
inhibition and IC50 values.
Ligands preparation
Using ChemDraw, studied compounds were drawn and geometrically optimized. 
 Using the DS standard Prepare Ligands protocol, pH based ionization was performed 
within a pH range of 7.0–7.6, and more importantly, different chemical tautomers were 
generated. In this study, multiple tautomeric configurations were used in order to account 
for receptor-induced tautomerization. For ellagic acid and myricetin, manual ionization 
was performed to match the ionization states reported in the literature.
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Preparation of the GLO-I enzyme
DS was used to prepare the crystal structure of the enzyme which was obtained from 
the Protein Data Bank (PDB). The PDB holds six records of GLO-I crystal structures with 
accession codes 3VW9, 3W0T, 3W0U, 1QIN, 1QIP, and 1FRO. The 3W0T crystal, which has 
the highest resolution (1.35 Å), was selected which corresponds to two units of GLO-I 
complexed with N-hydroxypyridone derivative inhibitor (HPU). The Protein Report tool 
within DS was used to check the quality of the crystal structure for missing loops, incom-
plete residues and alternate conformations. Then, one of the dimer units was deleted and 
the structure was cleaned using the Prepare Protein protocol within DS to correct con-
nectivity and bond order, standardize atom names, protonate protein at pH of 7.4, and keep 
one set of coordinates for residues with alternate conformation. There were seven amino 
acid residues with alternate conformation that are distant from the active site and have 
subtle conformational differences. Later, all ligands were deleted in order to solvate and 
minimize the apo-enzyme. The co-crystallized waters were not deleted in order not to 
create holes within the protein that will not be filled upon solvation. Finally, the structure 
was typed using the Simulation Tools by applying the CHARMm force field and it was 
ready for further modeling steps.
Solvation and minimization of the GLO-I enzyme
The prepared enzyme was explicitly solvated using a pre-equilibrated truncated 
 octahedral cell of TIP3 water (18) with a 7.0 Å minimum distance from the cell boundary. 
Then, it was neutralized by adding NaCl counterions at 0.145 mol L–1 ionic strength.  Finally, 
the solvated system was minimized using the smart minimizer algorithm within the Minimi-
zation protocol. The smart minimizer performs 1000 steps of Steepest Descent, followed 
by Conjugate Gradient minimization (19), and herein, 5000 steps of conjugate gradient 
minimization were used with a root mean square (RMS) gradient of 0.1 kcal mol–1 Å–1. The 
minimization step was subdivided into three stages in order to relax the system and 
 remove all potential clashes between the protein and the solvent without creating distor-
tions in the overall protein structure. In the first minimization stage, all heavy atoms were 
constrained, then only backbone atoms were constrained, and in the third stage all constrains 
were removed to allow free motion of the entire system.
Molecular docking and calculation of binding energies
The CDOCKER Docking protocol (20) was employed to dock the selected compounds 
into the active site of the GLO-I enzyme using default parameters with a final full potential 
minimization step. Finally, the binding free energies of all docked poses were calculated 
using the Calculate Binding Energy protocol, where implicit solvation using the Genera-
lized Born with Molecular Volume (MM-GBMV) model was applied (17).
In vitro enzyme assay
Human recombinant GLO-I (rhGLO-I) was used in the in vitro assay to measure the 
biological activity of selected compounds against GLO-I enzyme as previously detailed 
(9–11). Briefly, the enzyme was reconstituted in our lab and aliquots were stored at –70 °C. 
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Tested compounds were dissolved in DMSO, the final concentration of DMSO in the assay 
mixture was 0.5 %. A sodium phosphate assay buffer was used with a pH of 7.0–7.2. The 
substrate mixture was prepared by mixing the methylglyoxal solution with assay buffer. 
Finally, the tested compounds were mixed with the assay buffer, GLO-I enzyme, and sub-
strate solution mixture in a cuvette making a final compound concentration of 50 µmol L–1, 
then screened at λmax = 240 nm for 200 s at 37 °C. Each concentration was measured in 
triplicate. The IC50 values of the active compounds were calculated.
RESULTS AND DISCUSSION
Compounds selection
The aim of this study was to search for new scaffolds that can be utilized in designing 
more potent and selective GLO-I inhibitors and to further investigate the impact of ioniz-
ability and structural rigidity of polyphenolic compounds on their GLO-I inhibitory poten-
tial. Therefore, a set of structurally diverse polyphenolic natural compounds were selected 
for in silico evaluation. The set included three flavonolignans: isosylibin A, silychristin and 
isosilychristin; (–)-epicatechin (a flavonoid); and maesopsin (a flavonoid with a benzofura-
none scaffold). These compounds are lacking the C2-C3 olefinic bond in their flavonoid 
skeleton that was deemed critical for the activity (11). The compounds were selected to fur-
ther test the validity of our previous SAR conclusions. Additionally, cardamonin, a chalcone, 
and dihydrocaffeic and chlorogenic acids that are hydroxycinnamic acid derivatives were 
also included. All of the three compounds are lacking the 3-ring system of flavonoids, yet, 
they are poly-hydroxylated phenols with a carboxylate moiety (not cardamonin) that is 
known to be a good zinc binder. Moreover, they have some structural resemblance to trans- 
-stilbenes of which piceatannol has been proved to have good GLO-I inhibitory activity (21). 
The last compound selected was ellagic acid, a symmetrical dimeric derivative of gallic acid, 
which is a polyphenol with a unique rigid and planar structural scaffold.
Ligands preparation
The ionization state of a ligand affects its binding interactions with the GLO-I  enzyme. 
Since most of the selected compounds are polyphenols that have different ionization states 
at different pHs it is important to verify the output of ligand preparation step. Therefore, 
the prepared ligands were inspected in order to check how the Prepare Ligands protocol 
performed the ionization step in the specified pH range.
In the pH range of 7.0–7.6 the Prepare Ligand protocol generated two ionization states 
of ellagic acid, unionized, and ionized with a net charge of –1, based on the hydroxyl group 
ionization on equivalent C2 and C7 carbon atoms. For myricetin, the Prepare Ligand pro-
tocol generated only one ionization state with a net charge of –2 (Fig. 2). However, the pKa 
values of ellagic acid are reported to be (pKa1 = 5.42 ± 0.01 and pKa2 = 6.76 ± 0.02) in aqueous 
media (22, 23), which are lower than that of myricetin (6.63 ± 0.09) (24). Moreover, Simic et 
al. (22) have reported that in the pH range of 4.8–7.6, all three ellagic acid forms exist 
(unionized, monoanion and dianion), while at pH higher than 7.6 the dianion predomi-
nates (22). Nonetheless, there are some controversies about the first deprotonable OH 
group (the most acidic) in ellagic acid: whether they are the (C3-OH, C8-OH) or the (C2-
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OH, C7-OH) (23, 25, 26). Further, it has been predicted that the physiological net charges of 
ellagic acid and myricetin are –2 and –1, resp. (as per DrugBank, https://www.drugbank.
ca), which agrees with the reported pKa values of the two compounds and the ionization 
forms of ellagic acid at different pHs. Moreover, it has been reported that for flavones such 
as myricetin the most acidic site is the 4’-hydroxyl group (27), however, in other reports the 
7-hydroxyl group was considered the most favored deprotonation site (28).
Therefore, in order to enhance the accuracy of the docking results, all possible physi-
ological ionization states of the two compounds were manually prepared based on data 
reported in the literature (22–24, 27–29) (Fig. 2). Moreover, quantum mechanics (QM) cal-
culations were performed for ellagic acid and myricetin to confirm the most likely ioniza-
tion form for each compound (Table I). Then, different tautomers of the two edited com-
pounds were generated using Prepare Ligands protocol and were then docked into the 
GLO-I active site along with other prepared compounds in the selected set.
Fig. 2. The different ionization states of ellagic acid and myricetin as reported in the literature (22–24) 
(colored black) compared to those obtained from the Prepare Ligand protocol in DS (colored red).
Table I. QM-based partial charges of the most ionizable hydrogens in ellagic acid and myricetin
Compound Atom name and IDa
Partial charges (DMol3)
Mulliken method Hirshfeld method
Ellagic acid
H26 and H28 + 0.333 + 0.181
H25 and H27 + 0.328 + 0.205
Myricetin 
H of the C7-OH + 0.362 + 0.210
H of the C4’-OH + 0.357 + 0.200
QM – quantum mechanics
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QM calculations were performed using the Calculate Energy (DFT) protocol within 
DS which performs density functional QM calculation using DMol3 (29). Default parame-
ters were used except for the function for which the hybrid B3LYP functional was used, 
the quality of calculations was set to fine and using water as the solvent. The atomic charges 
were calculated using the Mulliken (25) and the Hirshfeld methods (26). QM results were 
similar to those reported in the literature where the most ionizable hydroxyl group in 
 ellagic acid was variable depending on the QM method, yet, the values of the partial charges 
were quite close. For myricetin, the C7-OH seems to be the most ionizable group with little 
difference from the C4’-OH.
Preparation of the GLO-I model
The initial coordinates of GLO-I were obtained from X-ray crystallography, which 
usually suffers artifacts such as crystal packing. Therefore, in order to generate a relaxed 
and more realistic protein conformation, the prepared apo-enzyme was solvated and 
mini mized. The prepared apo-GLO-I model was explicitly solvated with a TIP3P water 
truncated octahedral solvation cell in order to better mimic the experimental conditions. 
Then, the minimization of the solvated system relieved crystal strain and drove the system 
into a local minimum. Examination of the six solved crystal complexes of GLO-I enzyme 
available in the PDB showed no direct involvement of structural water in ligand binding, 
hence, all water molecules and counterions, NaCl, were deleted from the minimized 
 solvated system and the protein was ready to be used in subsequent molecular docking.
Molecular docking and calculation of binding energies
Molecular docking is a valuable and frequently used method in structure-based drug 
design (SBDD). This is due to its ability to predict the binding configuration of a docked 
ligand and to estimate its binding affinity within the virtual complex (30). Among the 
limitations of current scoring functions that affect binding affinity prediction is the limited 
treatment of the solvation effect (31). One of the ways to alleviate this problem and improve 
the accuracy of binding affinity prediction is to apply physics-based scoring, e.g., MM-PB/SA, 
MM-GB/SA, and MM-GBMV (MM stands for molecular mechanics, PB and GB for Poisson- 
-Boltzmann and Generalized Born, resp., SA for solvent-accessible surface area, and MV 
for molecular volume) (32).
CDOCKER, which is a grid-based molecular docking algorithm that utilizes the 
CHARMm force field (17, 20), was used in this study to dock the selected compounds into 
the active site of the GLO-I enzyme. However, it is customary to validate the docking 
method (the perception of the active site by the docking algorithm, and whether the active 
site is well defined or not) before taking it forward (docking the set of selected compounds) 
(33). This was achieved by redocking the co-crystallized ligand into the defined binding 
site and comparing the resultant poses with the co-crystallized ligand conformation, 
hence, testing the accuracy of the docking algorithm in recapitulating the co-crystallized 
ligand pose. The docking results were in excellent agreement with the co-crystallized 
HPU pose with a root mean square deviation (RMSD) of 0.896 Å. Afterward, the set of 
selected compounds were docked into the active site of the GLO-I enzyme using CDOCK-
ER algorithm with a final refinement step using grid-based simulated annealing and a 
full-force field minimization (Table II). The docked poses of the studied compounds were 
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ranked based on their –CDOCKER energy, which corresponds to ligand-receptor interac-
tion energy plus ligand strain, where higher values correspond to better binding affinity. 
The (–)CDOCKER energy scores were ranging from 14.65 kcal mol–1 for isosilychristin to 
55.39 kcal mol–1 for myricetin. 
The CDOCKER scoring function is a force field-based function (i.e., electrostatic and 
van der Waal interaction energies are summed up to total interaction energy based on 
which a ligand is scored and ranked) and is reported to have a docking success rate of 74 % 
(20), yet, it does not account for solvation/desolvation energy, entropy, or ΔG of binding. 
Therefore, a more rigorous method for estimating the binding energy of docked poses was 
used. Here, we implemented the MM-GBMV implicit solvent model, embedded within the 
calculate binding energy protocol in DS, to account for solvation/desolvation energy which 
improves the accuracy of ligand-protein binding affinity prediction (17, 32) (Table II). Prior 
to running the MM-GBMV protocol all docked poses were in situ minimized using the In 
Situ Ligand Minimization protocol in DS using default parameters except for the number 
of smart minimizer steps which was set to 5000. The binding free energy for a protein- 
-ligand complex can be calculated from the free energies of the complex, the protein, and 
the ligand according to the following equation.
EnergyBinding = EnergyComplex ‒ EnergyLigand ‒ EnergyProtein
Interestingly, the MM-GBMV calculations showed that ellagic acid had the highest 
binding energy score with 84.01 kcal mol–1, which is higher than that of myricetin, the 
positive control used in this study. The (–)binding free energies of the selected compounds 
were ranging from 4.30 kcal mol–1 for maesopsin to 84.01 kcal mol–1 for ellagic acid. The (–)
CDOCKER scores and binding energy values of the compounds (–)-epicatechin, cardamo-
nin, silychristin, maesopsin, and isosiliychristin (compounds 6–10) were ranging from 
14.65 to 29.81 kcal mol–1 and 7.32 to 24.41 kcal mol–1, resp., suggesting these compounds to 
be inactive or weakly active. Nonetheless, compounds 6–10, which are expected to be inac-
tive or weakly active, were biologically tested in order to assess the validity and accuracy 
of the applied in silico approach, when comparing predictions with experimental results. 
They were also needed to support previously drawn structure-activity relationship (SAR) 
of flavonoids as GLO-I inhibitors.
In vitro enzyme assay
The biological activities of the selected compounds against the GLO-I enzyme were 
evaluated using an in vitro enzyme assay. The selected compounds were initially screened 
at 50 mmol L–1 concentration and their percent of GLO-I inhibition was measured relative 
to myricetin (the positive control) (Table II).
The initial screening of the tested compounds showed that ellagic acid has the most 
potent inhibitory activity with GLO-I inhibition of 97.5 %, in perfect agreement with the 
MM-GBMV results, followed by chlorogenic acid and (–)-epicatechin that showed activi-
ties around one-half that of ellagic acid (52.3 and 45.5 %, resp.). This result demonstrates 
that the hydroxylation pattern and structural rigidity of ellagic acid could be a key factor 
for its pronounced activity against the GLO-I enzyme. Furthermore, the experimental results 
agree with the in silico ones regarding compounds’ expected activities; more details will 
be presented in the correlation section.
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Table II. Chemical structures of the studied compounds along with their CDOCKER energy scores, (–)
binding energy score and GLO-I inhibition
No. Chemical structure Name (–)CDEa (–)BE GLO-I inhibition (%)b,c
1 Myricetin 55.39 69.95 91.3 ± 2.9
2 Ellagic acid 48.03 84.01 97.5 ± 1.6
3 Dihydrocaffeic acid 43.24 31.99 17.4 ± 3.3
4 Chlorogenic acid 37.78 16.45 52.3 ± 7.3
5 Isosylibin A 29.94 31.33 28.4 ± 11.9
6 (–)-Epicatechin 29.81 7.32 45.5 ± 4.85
7 Cardamonin 26.77 24.41 32.5 ± 3.9
8 Silychristin 24.81 21.02 6.7 ± 5.8
9 Maesopsin 16.68 4.30 0.04 ± 0.03
10 Isosilychristin 14.65 22.41 6.4 ± 11.0
(–)BE – the negative value of the binding free energy calculated using the MM-GBMV model, (–)CDE – the negative 
value of CDOCKER energy
a Tested compound are sorted in a decreasing order of their (–)CDOCKER energy scores.
b Concentration: 50 mmol L–1.
c The data represents the mean ± SD of three independent experiments.
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Fig. 3. Dose-response curves and IC50 values of human GLO-I inhibition for ellagic acid compared to 
myricetin (the positive control). The shown results correspond to the mean ± SD of three independent 
experiments.
Following the determination of the percent of GLO-I inhibition by the tested com-
pounds, the dose-dependency of GLO-I inhibition by ellagic acid (2) was measured in order 
to determine its IC50 value (Fig. 3). The IC50 of ellagic acid was found to be 0.71 mmol L–1, 
about eightfold lower than that of myricetin (1) with IC50 of 5.44 mmol L–1. The percent of 
GLO-I inhibition by other compounds was ranging from 0.04 to 52.33 µmol L–1. Therefore, 
they were considered weakly active or inactive and the determination of their IC50 values 
was not pursued.
Correlation between the in silico and experimental results
The correlation between the in silico and experimental results was calculated using 
the Pearson correlation coefficient (34). The correlation coefficient (R) between the 
(–)CDOCKER energy scores using the solvated minimized enzyme and the % of GLO-I in-
hibition values for the tested compounds was found to be 0.84. This high value of R indicates 
a strong positive correlation, which means that high (–)CDOCKER scores, corresponding to 
high binding affinity, are paired with high % of GLO-I inhibition. Similarly, the correlation 
between the (–)binding free energy scores and the % of GLO-I inhibition values was 0.81, 
meaning that high binding energy values (stable complex) are paired with high % of GLO-I 
inhibition. Note that the CDOCKER and the Binding energy scores are reported as negative 
values (Table II), therefore a higher positive value indicates a more favorable binding.
Analysis of the docked poses of tested compounds
Compounds 5–10 were expected, based on the in silico results, and on our previously 
proposed SAR of flavonoids as GLO-I enzyme inhibitors (not 7, being lacking the C2-C3 
olefinic bond and/or the C4-keto functionalities) to be inactive or weakly active. The in silico 
results were in excellent agreement with the in vitro ones for these  compounds and sup-
ported our previous SAR conclusions. For example (–)-epicatechin is structurally similar 
to quercetin, an excellent GLO-I inhibitor, however, the lack of the  C2-C3 olefinic bond and 
the C4-keto functionalities has hampered its activity.
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Dihydrocaffeic acid (3) and chlorogenic acid (4) are lacking the common flavonoid ring 
system, yet, they are polyhydroxylated phenolic compounds with a good zinc chelating 
carboxylate moiety. Due to their different structures compared to common flavonoids and 
their good (–)CDOCKER and/or (–)binding energy scores we inspected their binding inter-
actions with the GLO-I active site. Inspection of the different docked poses of these com-
pounds showed that their interactions are quite interesting since they could serve as lead 
compounds worthy of further optimization (Fig. 4a).
In the case of chlorogenic acid (4), for the carboxylate moiety to be able to interact with 
Arg37, the compound needs to adopt a conformation that disrupts the interaction of the 
ester carbonyl with the zinc ion and vice versa. A possible structural modification of com-
pound 4 that could enhance its binding affinity is via replacing the cyclohexyl moiety with 
a planar aromatic analog. This could allow the carboxylate to establish strong electrostatic 
interactions with the positively charged Arg37 while maintaining effective zinc coordina-
tion by the ester functionality. This modification was simulated in silico, where the chiral, 
non-planar trihydroxy-cyclohexanecarboxylate moiety was replaced with a planar analog, 
gallic acid, (ellagic acid is a dimeric derivative of gallic acid). Then, the chlorogenic acid 
analog was docked to the GLO-I active site and a (–)CDOCKER score of 51.28 kcal mol–1 
was obtained, an intermediate value between that of myricetin and ellagic acid suggesting 
that this analog could be a potent GLO-I inhibitor. The docked poses of this analog re-
vealed interesting interactions with the GLO-I active site where the ionized carboxylate 
Fig. 4. a) The top-ranked docked poses of chlorogenic and dihydrocaffeic acids; b) Top-ranked docked 
pose of the proposed chlorogenic acid analog. Upper panel: 3D depiction of the docked poses. The 
GLO-I active site is shown as a hydrophobic surface, the docked compounds as sticks, and Zn ion as 
a purple sphere. Middle panel: 2D chemical structures of docked compounds. Lower panel: 2D rep-
resentation of the ligand-enzyme interactions, where residues engaged in these interactions are 
shown as discs colored according to the type of their interactions with the ligand.
a)                                                                                                        b)
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moiety is establishing strong interactions with His126 and Arg37 that were absent in the 
parent chlorogenic acid making it a plausible analog (Fig. 4b).
Dihydrocaffeic acid (3), on the other hand, can be considered as an efficient fragment. 
It is the smallest compound in the tested set, and yet, forms interesting interactions with 
zinc ion and the hydrophobic pocket. Structural optimization via evolution to a larger 
structure, for example, that can reach and interact with Arg37, besides the interactions it 
forms with the zinc ion and the hydrophobic pocket, could lead to a more potent derivative 
(Fig. 4a).
The binding interactions of ellagic acid with GLO-I active site
Interestingly, the in silico results had shown that ellagic acid (2) is the most active 
compound among the selected series which was approved by the in vitro biological assay. 
The excellent activity of ellagic acid, its novel scaffold and the numerous studies that high-
lighted its biological functions and benefits to human health (35, 36), necessitate further 
exploration of the binding mode of this promising compound within the GLO-I active site 
that could aid the design of more potent GLO-I inhibitors.
As stated previously, in order to investigate the effect of different ionization states and 
tautomeric forms of ellagic acid on its GLO-I binding affinity different tautomers with all 
possible physiological ionization states were prepared and docked into the GLO-I active 
site. All of the 10 top-ranked poses of ellagic acid based on (–)CDOCKER energy scores 
correspond to the ionized form of the compound, of which seven poses correspond to the 
Fig. 5. The three top-ranked docked poses of ellagic acid based on -CDOCKER energy scores. a) Top-
ranked pose (dianion-2); b) 2nd top-ranked pose (dianion-2); c) 3rd top-ranked pose (monoanion-2). 
Depictions of panels are as in Fig. 4.
a)                                           b)                                             c)
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Fig. 6. The top-ranked pose of each ionization state of ellagic acid based on MM-GBMV-binding energy 
values. Depictions of panels are as in Fig. 4.
dianion-2 and the other three corresponds to the monoanion-2 (Fig. 5), with a narrow (–)
CDOCKER energy range (45.48 to 48.03 kcal mol–1).
The orientation of the 10 top-ranked docked poses of ellagic acid is quite consistent in 
which ellagic acid establishes an electrostatic interaction, via its ionized hydroxyl group, 
with the Zn ion, along with numerous π-π interactions with Phe67 and Met65. In addition, 
in some poses, other types of interactions are also in places such as hydrogen bonding and 
other forms of hydrophobic interactions.
Similarly, in the refined docked poses of ellagic acid following in situ minimization 
and MM-GBMV calculations, seven of the 10 top-ranked poses based on (–)binding energy 
scores correspond to dianion-2, two correspond to monoanion-1 and one to dianion-1 with 
(–)binding energy scores ranging from 73.06 to 84.01 kcal mol–1 (Fig. 6).
The refined docked poses of ellagic acid show that the different ionized forms establish 
quite strong and effective interactions with the GLO-I active site including ionic, hydrogen 
bonding and π-π interactions. The main interactions were involving the electrostatic 
 attractive interactions between the ionized hydroxyl groups of ellagic acid and the Zn ion 
and Lys156, at the positively charged mouth of the enzyme, which only exists in the 
 dianion forms. Moreover, the ionized form with the highest (–)binding energy value was 
the dianion-2 and the first four poses among the 10 top-ranked ones were corresponding 
to this ionization form.
The relatively close values of (–)CDOCKER and (–)binding energy scores between the 
different ionization states of ellagic acid when combined with the orientation of their cor-
responding docked poses within the active site indicate that the mono- and di-ionized 
forms of ellagic acid can effectively bind the GLO-I active site and inhibit the activity of 
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the enzyme equally well. This agrees with the findings of Simic et al. (22) who reported 
that in the pH range of 4.8–7.6 all three ellagic acid ionization forms exist.
However, the dianion-2 was the predominant ionization form of ellagic acid and is the 
one that showed the highest (–)CDOCKER and (–)binding energy scores to which the pro-
nounced activity of the compound is likely to be attributed. Collectively, the pronounced 
activity and potency of ellagic acid are attributed to its numerous interactions formed with 
the GLO-I enzyme besides its shape and geometry which ultimately result in a complete 
blockade of the active site.
CONCLUSIONS
The aim of this study was to search for a potent GLO-I inhibitor. The present compu-
tational work revealed that ellagic acid could lead to an energetically stable complex and 
thus favorable binding with GLO-I enzyme which was supported and confirmed by the in 
vitro enzyme assay that showed an IC50 value of ellagic acid of 0.71 mmol L–1. Binding of 
ellagic acid to the GLO-I active site seems to be mainly driven by attractive interaction 
between its dianion form and the Zn ion and Lys156 along with numerous hydrogen 
 bonding and hydrophobic interactions. Based on the current evidence, ellagic acid can be 
 utilized, due to its unique and rigid scaffold, to search for other novel and potent GLO-I 
 inhibitors via computational approaches such as pharmacophore modeling and similarity 
search methods. Besides, chlorogenic acid and dihydrocaffeic acid can be considered as 
lead compounds that are worthy of optimization towards designing more potent GLO-I 
inhibitors. Moreover, it is important to check the accuracy of used algorithms in preparing 
ligands (ionization in our case) before proceeding further in modeling steps, since inac-
curate preparation could result in misleading results. Finally, given the excellent activity 
of ellagic acid and its cost-effectiveness relative to myricetin it could be used as a positive 
control in GLO-I enzyme inhibition assays instead of myricetin.
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